|
Apolipoprotein A-I Gene Polymorphism and Atherosclerosis Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Apolipoprotein A-I Gene Polymorphism and Atherosclerosis conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Apolipoprotein A-I Gene Polymorphism and Atherosclerosis Clinical research trials and Apolipoprotein A-I Gene Polymorphism and Atherosclerosis health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Apolipoprotein A-I Gene Polymorphism and Atherosclerosis. Apolipoprotein A-I Gene Polymorphism and Atherosclerosis Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Apolipoprotein A-I Gene Polymorphism and Atherosclerosis clinical trial. Human subjects often get the best healthcare possible for their Apolipoprotein A-I Gene Polymorphism and Atherosclerosis condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Apolipoprotein A-I Gene Polymorphism and Atherosclerosis  Apolipoprotein A-I Gene Polymorphism and Atherosclerosis
Apolipoprotein A-I Gene Polymorphism and Atherosclerosis
For Condition: Cardiovascular Diseases,Coronary Arteriosclerosis,Heart Diseases,Atherosclerosis
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To further define the linkage of the Apo A-I gene polymorphism to genetic high density lipoprotein (HDL) deficiency and premature coronary artery disease. Also, to utilize this gene marker to define the prevalence of genetic HDL deficiency in patients with premature coronary disease and to determine the relative risk of premature coronary disease associated with the Apo A-I gene polymorphism.
Details: BACKGROUND: Apolipoprotein (apo) A-I is the major protein constituent of plasma high density lipoproteins (HDL). HDL has been shown to promote cholesterol efflux from cells in vitro. Decreased plasma concentrations of HDL cholesterol and Apo A-I have been associated with premature coronary artery disease due to atherosclerosis in our society. A genetic HDL deficiency, familial hypoalphalipoproteinemia, appears to be fairly common in patients with premature coronary artery disease. The gene for Apo A-I has been isolated and characterized. Preliminary studies indicate that a specific Apo A-I gene polymorphism, detected following Pst I restriction enzyme digestion utilizing a specific probe, is significantly more common in subjects with premature coronary artery disease than in normal control subjects, and in some kindreds is associated with genetic HDL deficiency. This Apo A-I gene polymorphism is due to an alteration in the Apo A-I, Apo C-III intergenic region, near the 3' end of the coding region for Apo A-I. These observations have important implications for the detection of individuals genetically predisposed to premature coronary disease, as well as for providing insights into the mechanism leading to atherosclerosis. DESIGN NARRATIVE: Questionnaires were used to obtain information from each patient on known risk factors and diet. Fasting blood samples were obtained for lipoprotein analysis. Standard clinical and cardiological information and fasting blood samples were also collected for the cases. Blood was drawn for the DNA studies. A determination was made as to whether the Pst I Apo A-I gene polymorphism was associated with diminished levels of plasma Apo A-I or HDL cholesterol, by analysis of the distribution of these variables in cases and controls, after controlling for other known risk factors. Linkage analysis was used to determine whether the Pst I Apo A-I gene polymorphism co-segregates with premature coronary disease, or with diminished levels of plasma Apo A-I, or HDL cholesterol in 50 kindreds. A characterization was made of the abnormality in the Apo A-I, Apo C-III, Apo A-IV gene complex in patients with HDL deficiency, premature coronary disease, and the Pst I Apo A-I gene polymorphism.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Male
Protocol Entry Criteria: No eligibility criteria
Total Enrollment:
Location and Contact Information:
Additional Information:
Study ID Numbers: 1061;
Study Start Date: December 1985
Record last reviewed: April 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005183
Other Atherosclerosis Studies:
1. Trial of Smoking Cessation Programs in Black Churches
2. IN CONTROL--Hypertension Reduction in Inner City Seattle
3. Molecular & Clinical Evaluation of Low HDL Syndromes
4. Multicenter Investigation of Limitation of Infarct Size (MILIS)
5. CVD Risk Factors and Sexual Identity in Women
Related Studies:
Other Atherosclerosis Clinical Trials
Other Clinical Trials
Other Clinical Trials
Apolipoprotein A-I Gene Polymorphism and Atherosclerosis
|
|
|
|
|
|
|
|
